Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Rhea-AI Summary

Innate Pharma (Nasdaq: IPHA) has announced its upcoming Annual General Meeting scheduled for May 22, 2025 at 10:30 a.m. CEST at their headquarters in Marseille, France. The meeting's Notice was published on April 16, 2025.

Key features of the AGM include:

• Live broadcast available online
• Guided laboratory tour for shareholders at 9:15 a.m. CEST
• Shareholders must register shares two business days prior to AGM
• Bearer shareholders need to obtain certificate of shareholding from brokers
• Written questions must be submitted four business days before the AGM

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its annual general meeting of shareholders (“AGM”) at 10:30 a.m. CEST on May 22, 2025 in its headquarters, 117 avenue de Luminy, 13009 Marseille.

The Notice of Meeting of this AGM was published on April 16, 2025 in the French legal bulletin. It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM.

Documents and information relating to this meeting will be made available to shareholders in accordance with current regulations, and will also be available in the Investors section of the Company's website.

****

The annual general meeting will also be broadcasted live and available at the following link:

Innate Pharma 2025 annual general meeting

A guided tour of the Company's laboratories is organized on the same day at 9:15 a.m. CEST for shareholders. Shareholders can register for the tour at this link: company laboratories tour registration form.

****

Precision regarding the AGM:

Only shareholders having registered their shares at least two business days prior to the date of the AGM, by zero hour Paris time, will be able to participate.

Shareholders holding “au porteur” (bearer) shares will need to obtain an “attestation de participation” (certificate of shareholding) from their brokers. This “attestation de participation” must be attached to the voting or proxy form.

Written questions from shareholders must be received four business days prior to the AGM at the latest (by e-mail to investors@innate-pharma.fr).

Shareholders can also obtain the documents and information in preparation of the AGM (as described in article R. 225-83 of the French Code de Commerce) by sending a request by e-mail to investors@innate-pharma.fr.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET^® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com. Follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code Ticker code LEI

FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250415963401/en/

For additional information, please contact:

Investors

Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Source: Innate Pharma SA

FAQ

When and where is Innate Pharma (IPHA) holding its 2025 Annual General Meeting?

Innate Pharma's AGM will be held on May 22, 2025 at 10:30 a.m. CEST at their headquarters in Marseille, France (117 avenue de Luminy, 13009).

What are the key deadlines for IPHA shareholders to participate in the 2025 AGM?

Shareholders must register shares 2 business days before the AGM and submit written questions 4 business days prior to the meeting.

How can shareholders participate in Innate Pharma's (IPHA) 2025 AGM?

Shareholders can attend in person, watch via live broadcast, or vote by proxy. Bearer shareholders must obtain a certificate of shareholding from their brokers.

What special events are planned for IPHA's 2025 Annual General Meeting?

A guided tour of the company's laboratories is organized for shareholders at 9:15 a.m. CEST on the same day as the AGM.